RU2016127357A - Модулятор сетр для применения в лечении заболеваний глаз - Google Patents
Модулятор сетр для применения в лечении заболеваний глаз Download PDFInfo
- Publication number
- RU2016127357A RU2016127357A RU2016127357A RU2016127357A RU2016127357A RU 2016127357 A RU2016127357 A RU 2016127357A RU 2016127357 A RU2016127357 A RU 2016127357A RU 2016127357 A RU2016127357 A RU 2016127357A RU 2016127357 A RU2016127357 A RU 2016127357A
- Authority
- RU
- Russia
- Prior art keywords
- amd
- neovascularization
- eye diseases
- eye
- pharmaceutical composition
- Prior art date
Links
- 208000030533 eye disease Diseases 0.000 title claims 11
- 206010064930 age-related macular degeneration Diseases 0.000 claims 17
- 208000002780 macular degeneration Diseases 0.000 claims 17
- 238000000034 method Methods 0.000 claims 9
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 9
- KEWSCDNULKOKTG-UHFFFAOYSA-N 4-cyano-4-ethylsulfanylcarbothioylsulfanylpentanoic acid Chemical compound CCSC(=S)SC(C)(C#N)CCC(O)=O KEWSCDNULKOKTG-UHFFFAOYSA-N 0.000 claims 8
- 102100037637 Cholesteryl ester transfer protein Human genes 0.000 claims 8
- 208000005590 Choroidal Neovascularization Diseases 0.000 claims 8
- 206010060823 Choroidal neovascularisation Diseases 0.000 claims 8
- 101000880514 Homo sapiens Cholesteryl ester transfer protein Proteins 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 235000021466 carotenoid Nutrition 0.000 claims 5
- 150000001747 carotenoids Chemical class 0.000 claims 5
- 235000012680 lutein Nutrition 0.000 claims 5
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 5
- 239000001656 lutein Substances 0.000 claims 5
- 229960005375 lutein Drugs 0.000 claims 5
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 5
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 5
- JKQXZKUSFCKOGQ-JLGXGRJMSA-N (3R,3'R)-beta,beta-carotene-3,3'-diol Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-JLGXGRJMSA-N 0.000 claims 4
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 201000002563 Histoplasmosis Diseases 0.000 claims 4
- 208000017442 Retinal disease Diseases 0.000 claims 4
- 206010038923 Retinopathy Diseases 0.000 claims 4
- 206010038934 Retinopathy proliferative Diseases 0.000 claims 4
- JKQXZKUSFCKOGQ-LQFQNGICSA-N Z-zeaxanthin Natural products C([C@H](O)CC=1C)C(C)(C)C=1C=CC(C)=CC=CC(C)=CC=CC=C(C)C=CC=C(C)C=CC1=C(C)C[C@@H](O)CC1(C)C JKQXZKUSFCKOGQ-LQFQNGICSA-N 0.000 claims 4
- QOPRSMDTRDMBNK-RNUUUQFGSA-N Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCC(O)C1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C QOPRSMDTRDMBNK-RNUUUQFGSA-N 0.000 claims 4
- JKQXZKUSFCKOGQ-LOFNIBRQSA-N all-trans-Zeaxanthin Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2=C(C)CC(O)CC2(C)C JKQXZKUSFCKOGQ-LOFNIBRQSA-N 0.000 claims 4
- 208000001309 degenerative myopia Diseases 0.000 claims 4
- 230000004340 degenerative myopia Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 208000028867 ischemia Diseases 0.000 claims 4
- 208000006542 von Hippel-Lindau disease Diseases 0.000 claims 4
- 235000010930 zeaxanthin Nutrition 0.000 claims 4
- 239000001775 zeaxanthin Substances 0.000 claims 4
- 229940043269 zeaxanthin Drugs 0.000 claims 4
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 3
- 206010029113 Neovascularisation Diseases 0.000 claims 3
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 3
- 210000004087 cornea Anatomy 0.000 claims 3
- 201000000159 corneal neovascularization Diseases 0.000 claims 3
- 229940076783 lucentis Drugs 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 235000008210 xanthophylls Nutrition 0.000 claims 3
- 150000003735 xanthophylls Chemical class 0.000 claims 3
- WLCZTRVUXYALDD-IBGZPJMESA-N 7-[[(2s)-2,6-bis(2-methoxyethoxycarbonylamino)hexanoyl]amino]heptoxy-methylphosphinic acid Chemical compound COCCOC(=O)NCCCC[C@H](NC(=O)OCCOC)C(=O)NCCCCCCCOP(C)(O)=O WLCZTRVUXYALDD-IBGZPJMESA-N 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000022873 Ocular disease Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 201000005667 central retinal vein occlusion Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 229940092110 macugen Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229920001903 high density polyethylene Polymers 0.000 claims 1
- 239000004700 high-density polyethylene Substances 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 210000001525 retina Anatomy 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000001957 retinal vein Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 150000003749 zeaxanthins Chemical class 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D1/00—Rigid or semi-rigid containers having bodies formed in one piece, e.g. by casting metallic material, by moulding plastics, by blowing vitreous material, by throwing ceramic material, by moulding pulped fibrous material or by deep-drawing operations performed on sheet material
- B65D1/02—Bottles or similar containers with necks or like restricted apertures, designed for pouring contents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mechanical Engineering (AREA)
- Ceramic Engineering (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13198668.9 | 2013-12-19 | ||
| EP13198668 | 2013-12-19 | ||
| PCT/EP2014/077855 WO2015091410A1 (en) | 2013-12-19 | 2014-12-16 | Cetp modulator for use in the treatment of eye disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016127357A true RU2016127357A (ru) | 2018-01-24 |
Family
ID=49880487
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016127357A RU2016127357A (ru) | 2013-12-19 | 2014-12-16 | Модулятор сетр для применения в лечении заболеваний глаз |
Country Status (11)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX370538B (es) | 2013-03-27 | 2019-12-17 | Hoffmann La Roche | Marcadores genéticos para la predicción de respuesta a la terápia. |
| WO2016016157A1 (en) | 2014-07-30 | 2016-02-04 | F. Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| WO2025093129A1 (en) * | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025093436A1 (en) * | 2023-11-01 | 2025-05-08 | Newamsterdam Pharma B.V. | Treatment and prevention of age-related macular degeneration using a cetp inhibitor |
| WO2025146262A1 (en) * | 2024-01-03 | 2025-07-10 | Newamsterdam Pharma B.V. | Obicetrapib for use in the treatment of hemoglobinopathies |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| WO2003063848A1 (en) | 2002-01-30 | 2003-08-07 | Dsm Ip Assets B.V. | Lutein/zeaxanthin for glare protection |
| KR20080008440A (ko) * | 2003-03-17 | 2008-01-23 | 니뽄 다바코 산교 가부시키가이샤 | Ｃｅｔｐ 억제제의 약제학적 조성물 |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| US8212063B2 (en) | 2006-05-10 | 2012-07-03 | Omniactive Health Technologies Limited | Xanthophyll composition containing trans, meso-zeaxanthin, trans, R, R-zeaxanthin and trans, R, R-lutein useful for nutrition and health care and a process for its preparation |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| WO2009129859A1 (en) | 2008-04-24 | 2009-10-29 | Dr. Gerhard Mann Chem.-Pharm. Fabrik Gmbh | Compositions and methods for maintaining, strengthening, improving, or promoting eye health |
| WO2010074940A1 (en) * | 2008-12-23 | 2010-07-01 | Alcon Research, Ltd. | Compositions and nutritional supplements for improving ocular health and reducing ocular inflammatory response |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
| MY164729A (en) | 2010-11-04 | 2018-01-30 | Hoffmann La Roche | A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium |
| JP2014504605A (ja) * | 2011-01-25 | 2014-02-24 | ネステク ソシエテ アノニム | 動物の視覚系の劣化を治療、緩和又は予防するための方法及び組成物 |
| US20120301439A1 (en) * | 2011-05-24 | 2012-11-29 | Washington University | Inhibition of choroidal neovascularization |
| BR112015003658B1 (pt) * | 2012-08-21 | 2022-09-27 | Opko Pharmaceuticals, Llc | Formulação oftálmica, uso da dita formulação no tratamento de doença oftálmica do segmento posterior, formulação de lipossomas e suspensão oftálmica lipossomal |
-
2014
- 2014-12-16 BR BR112016013923A patent/BR112016013923A2/pt not_active Application Discontinuation
- 2014-12-16 MX MX2016005505A patent/MX2016005505A/es unknown
- 2014-12-16 JP JP2016541415A patent/JP6539661B2/ja not_active Expired - Fee Related
- 2014-12-16 CA CA2924401A patent/CA2924401A1/en not_active Abandoned
- 2014-12-16 RU RU2016127357A patent/RU2016127357A/ru unknown
- 2014-12-16 WO PCT/EP2014/077855 patent/WO2015091410A1/en not_active Ceased
- 2014-12-16 EP EP14812502.4A patent/EP3082784A1/en not_active Withdrawn
- 2014-12-16 EP EP19161186.2A patent/EP3524238A1/en not_active Withdrawn
- 2014-12-16 KR KR1020167016160A patent/KR20160093024A/ko not_active Withdrawn
- 2014-12-16 HK HK16112052.2A patent/HK1223827A1/zh unknown
- 2014-12-16 CN CN201480065543.XA patent/CN105792820A/zh active Pending
-
2016
- 2016-06-07 US US15/175,218 patent/US20160287537A1/en not_active Abandoned
-
2019
- 2019-04-03 US US16/374,045 patent/US20190224147A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017500340A (ja) | 2017-01-05 |
| HK1223827A1 (zh) | 2017-08-11 |
| JP6539661B2 (ja) | 2019-07-03 |
| EP3082784A1 (en) | 2016-10-26 |
| US20190224147A1 (en) | 2019-07-25 |
| MX2016005505A (es) | 2016-07-22 |
| WO2015091410A1 (en) | 2015-06-25 |
| KR20160093024A (ko) | 2016-08-05 |
| CA2924401A1 (en) | 2015-06-25 |
| BR112016013923A2 (pt) | 2017-08-08 |
| CN105792820A (zh) | 2016-07-20 |
| US20160287537A1 (en) | 2016-10-06 |
| EP3524238A1 (en) | 2019-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ610230A (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| IL272913B1 (en) | A low volume pre-filled syringe is sterilized | |
| HK1201438A1 (en) | Treatment of ocular disease | |
| JP2017500340A5 (cg-RX-API-DMAC10.html) | ||
| JP2008538215A5 (cg-RX-API-DMAC10.html) | ||
| MX349901B (es) | Uso de un antagonista de factor de crecimiento endotelial vascular para tratar transtornos oculares angiogenicos. | |
| MX2019013799A (es) | Peptido novedoso y composicion farmaceutica para tratar una enfermedad ocular que comprende el mismo como un ingrediente farmaceutico activo. | |
| MX2022006439A (es) | Compuestos para el tratamiento de enfermedades oculares asociadas con la vascularizacion excesiva. | |
| ES2722723T3 (es) | Métodos para tratar enfermedades oculares asociadas con inflamación y proliferación vascular | |
| RU2017125496A (ru) | Внутриглазная доставка биологически активных молекул с использованием ионтофореза | |
| TN2016000259A1 (en) | Salbutamol (albuterol) eye protective medicament. | |
| RU2016114724A (ru) | Применение n-(4-трет-бутилбензил)-3-хлор-n-[2-(4-хлор-3-этилфенил)-этил]-2-фтор-5-трифторметилбензамида для лечения глазных заболеваний | |
| JP2016532658A5 (ja) | 眼病の処置のためのＮ−（４−ｔｅｒｔ−ブチルベンジル）−３−クロロ−Ｎ−［２−（４−クロロ−３−エチル−フェニル）−エチル］−２−フルオロ−５−トリフルオロメチル−ベンズアミドを含む医薬組成物の使用 | |
| RU2014106328A (ru) | Фармацевтические композиции, содержащие 4-бром-n-(имидазолидин-2-илиден)-1н-бензимидазол-5-амин для лечения заболеваний сетчатки | |
| Kim et al. | Effects of senofilcon A mechanical protector on corneal endothelial cells during phacoemulsification in rabbit eyes: pilot study | |
| JP2014521648A5 (cg-RX-API-DMAC10.html) | ||
| JP2013513606A5 (cg-RX-API-DMAC10.html) | ||
| MY198731A (en) | Methods for treating ocular diseases | |
| Koh et al. | Fundus flavimaculatus and choroidal neovascularization in a young patient with normal electroretinography: case report | |
| Wang et al. | Clinical application of posterior continuous curvilinear capsulorhexis of posterior capsular rupture in the phacoemulsification | |
| Bikbov et al. | The results of the intrastromal corneal segments (Keraring) implantation for keratoconus | |
| Wen | Efficacy of internal limiting membrane peeling and vitrectomy with triamcinolone acetonide and silicone oil tamponade for the treatment of retinal detachment with choroidal detachment attributable to macular hole in high myopia | |
| RU2222297C2 (ru) | Способ отслойки задней пограничной мембраны | |
| AR119451A1 (es) | Proceso para la preparación de propionato de fluticasona acuoso oftálmico estéril a partir de suspensiones de nanocristales | |
| Ningshu et al. | Efficacy and safety of post-sclera injecting triamcinolone acetonide for diabetic macular edema |